Research Article
High Loss to Followup and Early Mortality Create Substantial Reduction in Patient Retention at Antiretroviral Treatment Program in North-West Ethiopia
Table 2
Baseline clinical characteristics of AIDS patients on ART at University of Gondar Hospital ART program, between March 2005 and August 2010.
| | Variable | Frequency (%) |
| | HIV disclosure status | | | Disclosed | 2260 (75.0) | | Not disclosed | 752 (25.0) | |
*Initial ART regimen | | | d4T-3TC-NVP | 1086 (36.1) | | d4T-3TC-EFV | 559 (18.6) | | d4T-3TC-NVP | 916 (30.4) | | d4T-3TC-EFV | 421 (14.0) | | Others | 30 (1.0) | | Initial regimen changed? | | | yes | 1537 (75.5) | | no | 498 (24.5) | | Baseline WHO stage | | | Stage I | 109 (3.6) | | Stage II | 372 (12.4) | | Stage III | 1980 (65.7) | | Stage iv | 551 (18.3) | | Baseline functional status | | | Functional | 1928 (64.0) | | Ambulatory | 766 (25.4) | | Bed ridden | 318 (10.6) | | Tuberculosis present | | | yes | 295 (26.7) | | No | 810 (73.3) | | Baseline CD4 cell count (cells/μL) | | | <50 | 586 (19.5) | | 50–200 | 682 (22.6) | | 201–350 | 1033 (34.3) | | >350 | 711 (23.6) |
|
|
*d4T: Stavudine; 3TC: Lamivudine; NVP: Nevirapine; EFV: Efavirenz; AZT: Zidouvudine; TDF: Tenofovir disoproxil fumarate.
|
